Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday positive data from global KOMET Phase III trial, in which Koselugo ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity ... and other organs.

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for ...

His company, Wilmette-based Monopar Therapeutics, announced yesterday it has entered a licensing deal with Alexion and its parent, AstraZeneca, to further develop ALXN-1840, or bis-choline ...

Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. ALXN-1840 has advanced through a Phase 3 clinical trial ...

A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio and pipeline in hematology, including from Alexion, its rare disease group ...

Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile ...